Trial Profile

A Phase 1 Study to Evaluate the Safety, Proliferation and Persistence of GEN-011, an Autologous Adoptive Cell Therapy Targeting Neoantigens in Solid Tumors

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 18 Jul 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GEN 011 (Primary) ; Cyclophosphamide; Fludarabine; Interleukin-2
Indications Anal cancer; Bladder cancer; Carcinoma; Head and neck cancer; Malignant melanoma; Merkel cell carcinoma; Non-small cell lung cancer; Pelvic cancer; Renal cancer; Renal cell carcinoma; Skin cancer; Small cell lung cancer; Solid tumours; Squamous cell cancer; Ureteral neoplasms; Urethral cancer; Urogenital cancer
Focus Adverse reactions; First in man
Acronyms TiTAN; TiTAN-1
Sponsors Genocea Biosciences [CEASED]

13 Jul 2022 Status changed from active, no longer recruiting to discontinued.
16 May 2022 Planned End Date changed from 1 May 2024 to 1 Jun 2022.
16 May 2022 Planned primary completion date changed from 1 May 2024 to 1 Jun 2022.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com